STOCK TITAN

Ingredion (NYSE: INGR) details next steps in Tate & Lyle all-cash acquisition

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Ingredion Incorporated provided an update on its planned all-cash acquisition of the entire issued and to be issued ordinary share capital of Tate & Lyle PLC. Tate & Lyle has published a Scheme Document under UK law, explaining the court-sanctioned scheme of arrangement that will be used to implement the deal.

Tate & Lyle will send this document to its shareholders ahead of a Court Meeting and a General Meeting scheduled for July 28, 2026, where shareholders will vote on the scheme and related resolutions. The disclosure emphasizes that this is not an offer or solicitation in itself and that shareholders should base any voting decisions solely on the information in the Scheme Document.

Positive

  • None.

Negative

  • None.

Insights

Procedural step in Ingredion’s Tate & Lyle acquisition, no new economics disclosed.

Ingredion reiterates its plan to acquire all ordinary shares of Tate & Lyle through a UK court-sanctioned scheme of arrangement. The key development is publication of the Scheme Document and scheduling of the shareholder Court Meeting and General Meeting on July 28, 2026.

The filing highlights that the scheme follows UK disclosure standards, which differ from U.S. tender offer and proxy rules, and that financials in the Scheme Document use UK accounting standards. It also notes the option to switch to a Takeover Offer, which would then comply with applicable U.S. regulations.

From an investment perspective, this looks like a routine procedural milestone in a previously announced transaction, rather than a change to valuation terms or strategic rationale. Future company communications and approvals around the July 28, 2026 meetings will determine whether the acquisition proceeds as planned.

Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Scheme Document publication date July 3, 2026 Date Tate & Lyle published Scheme Document
Shareholder meetings date July 28, 2026 Court Meeting and General Meeting for scheme votes
Scope of acquisition Entire issued and to be issued ordinary share capital Target of Tate & Lyle acquisition
Regulation FD regulatory
"Item 7.01 Regulation FD Disclosure."
Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.
scheme of arrangement regulatory
"intended to be implemented by means of a court-sanctioned scheme of arrangement"
A scheme of arrangement is a legal agreement between a company and its shareholders or creditors to reorganize or settle debts, often to avoid bankruptcy or make big changes. It’s like a carefully planned handshake that everyone agrees to, helping the company stay afloat or improve its financial health.
Takeover Offer regulatory
"if the Acquisition is implemented by way of a takeover offer, as that term is defined in the UK Companies Act (a “Takeover Offer”)"
A takeover offer is a proposal from one company or investor to buy enough shares of another company to gain control, usually by offering shareholders a higher price than the current market value. It matters to investors because accepting can deliver immediate cash and a premium on their shares, while rejecting may leave them in a company with a new owner whose strategy, management and future returns can change — like receiving an offer to buy your house that changes your neighborhood’s future.
tender offer rules regulatory
"A transaction effected by means of a scheme of arrangement is not subject to the tender offer rules"
Tender offer rules are the legal and procedural guidelines that govern a public offer to buy shareholders’ shares at a set price for a limited time. Think of them as the ground rules for a public sale or buyout—what information must be disclosed, how long the offer stays open, and how shareholders are treated—to ensure transparency and fair play. Investors care because these rules affect the price, timing, and protections available when deciding whether to sell their shares during a takeover attempt or buyback.
proxy solicitation rules regulatory
"not subject to the tender offer rules or the proxy solicitation rules under the Exchange Act"
Proxy solicitation rules are the legal guidelines that govern how individuals or groups ask shareholders for permission to vote on their behalf at corporate meetings, specifying what information must be disclosed, how and when solicitations can be made, and who may solicit. They matter to investors because those rules shape the fairness and transparency of contests over board seats and major decisions—like having clear rules for a neighborhood vote so people receive accurate information, time to decide, and protection from misleading tactics that could affect a company’s leadership and value.
accounting standards applicable in the United Kingdom financial
"financial information included in the Scheme Document has been prepared in accordance with accounting standards applicable in the United Kingdom"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
0001046257FALSE00010462572026-07-032026-07-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 3, 2026
Ingredion_Logo_SM_rgbHEX.gif
INGREDION INCORPORATED
(Exact name of registrant as specified in its charter)
Delaware 1-13397 22-3514823
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification No.)
5 Westbrook Corporate Center, Westchester, Illinois
 60154
(Address of principal executive offices) (Zip Code)
(708) 551-2600
(Registrant’s telephone number, including area code) 
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareINGRNew York Stock Exchange




Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  
 




Item 7.01    Regulation FD Disclosure.
On July 3, 2026, Tate & Lyle PLC, a company incorporated in England and Wales (“Tate & Lyle”), published a document (the “Scheme Document”) relating to the previously announced recommended cash acquisition by Ingredion Incorporated (the “Company”) of the entire issued and to be issued ordinary share capital of Tate & Lyle (the “Acquisition”), which is intended to be implemented by means of a court-sanctioned scheme of arrangement (the “Scheme”) under Part 26 of the UK Companies Act 2006 (the “UK Companies Act”). Tate & Lyle will deliver the Scheme Document to its shareholders in connection with a meeting of the shareholders to be convened by order of the High Court of Justice in England and Wales pursuant to Part 26 of the UK Companies Act to vote on approval of the Scheme (the “Court Meeting”) and a general meeting of the shareholders to be convened immediately after conclusion of the Court Meeting (the “General Meeting”) to vote on approval of shareholder resolutions necessary to approve, implement and effect the Scheme and the Acquisition. The Court Meeting and the General Meeting are scheduled to be held on July 28, 2026.
The information furnished in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Exchange Act or the Securities Act of 1933, as amended, except to the extent that the Company specifically incorporates any of the information by reference.
Further Information; No Offer or Solicitation
This report is for information purposes and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the all-cash offer by the Company for the entire issued and to be issued ordinary share capital of Tate & Lyle, or otherwise, nor shall there be any sale, issuance or transfer of securities of Tate & Lyle in any jurisdiction in contravention of applicable law. The Acquisition will be made solely by means of a Scheme (or, if the Acquisition is implemented by way of a takeover offer, as that term is defined in the UK Companies Act (a “Takeover Offer”), the offer document), which will contain the full terms and conditions of the Acquisition, including details of how to vote in respect of the Scheme. Any vote in respect of the Scheme or other response in relation to the Acquisition should be made only on the basis of the information contained in the Scheme Document (or, if the Acquisition is implemented by way of a Takeover Offer, the offer document). Tate & Lyle shareholders are urged to read the Scheme Document because it contains important information relating to the Acquisition.
Additional Information
The Acquisition is being made to acquire the shares of an English company by means of a scheme of arrangement provided for under English law. A transaction effected by means of a scheme of arrangement is not subject to the tender offer rules or the proxy solicitation rules under the Exchange Act. Accordingly, the Scheme is subject to disclosure requirements and practices applicable in the United Kingdom to schemes of arrangement, which are different from the disclosure requirements of the U.S. tender offer and proxy solicitation rules. The financial information included in the Scheme Document has been prepared in accordance with accounting standards applicable in the United Kingdom and thus may not be comparable to financial information of U.S. companies or companies whose financial statements are prepared in accordance with generally accepted accounting principles in the United States. If the Company exercises its right to implement the Acquisition by way of a Takeover Offer, such offer will be made in compliance with applicable U.S. laws and regulations.






SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 6, 2026  Ingredion Incorporated
  By: /s/ Tanya M. Jaeger de Foras
   
Tanya M. Jaeger de Foras
Senior Vice President, Chief Legal Officer,
Corporate Secretary and Chief Compliance Officer
   



FAQ

What acquisition does Ingredion (INGR) describe in this 8-K filing?

Ingredion describes a recommended all-cash acquisition of the entire issued and to be issued ordinary share capital of Tate & Lyle PLC. The deal is intended to be completed via a UK court-sanctioned scheme of arrangement under Part 26 of the UK Companies Act 2006.

What is the purpose of the Tate & Lyle Scheme Document mentioned by Ingredion (INGR)?

The Scheme Document explains the terms, conditions, and mechanics of the planned acquisition and scheme of arrangement. Tate & Lyle will send it to shareholders so they can understand the transaction and vote on the scheme and necessary resolutions at upcoming shareholder meetings.

When will Tate & Lyle shareholders vote on the Ingredion (INGR) acquisition?

Tate & Lyle shareholders are scheduled to vote on the scheme of arrangement and related resolutions at a Court Meeting and a General Meeting on July 28, 2026. These meetings will decide whether the scheme and the proposed all-cash acquisition move forward.

Is the Ingredion (INGR) update an offer to buy or sell securities?

No. The report states it is for information purposes only and does not constitute an offer, invitation, or solicitation to buy, sell, or subscribe for any securities. Any decision by shareholders should rely on the detailed information in the Scheme Document or a future offer document.

How does the Tate & Lyle scheme of arrangement differ from a U.S. tender offer?

A scheme of arrangement follows UK legal and disclosure requirements, not U.S. tender offer or proxy rules. The filing notes the Scheme will use UK practices and accounting standards, which may differ from those of U.S. companies and U.S. securities regulations.

Could Ingredion (INGR) implement the Tate & Lyle acquisition as a Takeover Offer instead of a scheme?

Yes. The company reserves the right to implement the acquisition as a Takeover Offer as defined in the UK Companies Act. If it does so, any such offer would be made in compliance with applicable U.S. laws and regulations governing tender offers.

Filing Exhibits & Attachments

3 documents